TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

292 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

140 studies on the map

Molecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoBone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait — UConn Health, FarmingtonA Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring — Pfizer, New YorkAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — Investigative Site, Beverly HillsEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaMetabolic Profiling of Immune Responses in Immune-mediated Diseases — National Institutes of Health Clinical Center, BethesdaCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaRegistry for Systemic Eczema Treatments — Johns Hopkins University, BaltimoreStress Management and Mindfulness Intervention for Patients With Sickle Cell Disease — University of Pennsylvania, PhiladelphiaUS Zamto-cel Autoimmune Diseases — Froedtert Hospital and the Medical College of Wisconsin, MilwaukeeDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonSMYLS Multi-site Trial — Medical University of South Carolina, CharlestonSickle Cell Improvement: Enhancing Care in the Emergency Department — Children's Wisconsin, MilwaukeeIntegrative Medicine in Pain Management in Sickle Cell Disease, 2.0 — Indiana University School of Medicine, IndianapolisA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandVerifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease — Cincinnati Children's Hospital Medical Center, CincinnatiSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — Research Site 4, Redwood CityComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamAdvancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease — Children's National Hospital, Washington D.C.The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamFunctional Ovarian Reserve in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamMindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease — University of Illinois Chicago, ChicagoA Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 — University of Colorado, Denver, DenverA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — Climb Bio Investigative Site #100104, AllenA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) — Wallace & Lee Center, Beverly HillsDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreBlood Sampling for Research Related to Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaSystemic Lupus Erythematosus in Gullah Health — Medical University of South Carolina, CharlestonResearch Accelerated by You Lupus Registry — Online Registry - No Physical Site Required, Washington D.C.Cutaneous Lupus Registry — University of Texas Southwestern Medical Center Dallas, DallasA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraPredictors of Pain in Sickle Cell Disease — Duke University Medical Center, DurhamA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants — Local Institution - 0062, MesaA Real-World Registry of Chronic Wounds and Ulcers — US Wound Registry, The WoodlandsArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaNatural History and Genetics of Food Allergy and Related Conditions — National Institutes of Health Clinical Center, BethesdaA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixATHNdataset Registry — American Thrombosis and Hemostasis Network, HickoryVirtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises — University of Maryland Medical Systems, BaltimoreBrief Pain Exposure Therapy (BPET) For Nociplastic Pain — University of Michigan, Ann ArborMaternal Autoimmune Disease Research Alliance (MADRA) Registry — Duke University, DurhamStudy to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population — Syneos Health (remote site), MorrisvilleTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease — Children's Hospital of Atlanta: Eagelston, AtlantaGenotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaThe Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study — University of California, San Francisco, San FranciscoA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease — Wallace Rheumatic Center, Beverly HillsRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonRheumatology Diet Study — UCF Health Clinics, OrlandoBAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus — Nationwide Children's, ColumbusA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterThe BRIDGE Pain Study — Cincinnati Children's Hospital, CincinnatiPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoSickleFit Exercise and Nutrition Study — Duke University, DurhamFlourish: Exploring the Early Infant Gut Microbiome — Seeding Labs INC, AustinPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnMetabolic and Hemodynamic Reserve in Pediatric SCA — Washington University in St. Louis, St LouisSchool Readiness Intervention for Preschool Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaA Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease — University of Florida, GainesvilleEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonSickle Cell, Pain and Mediterranean Diet — University of Illinois Chicago, ChicagoA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — Life Clinical Trials - Colonial Drive - Margate /ID# 276050, MargateTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomIntervention to Improve Communication and Medication Adherence in Lupus — Duke University, DurhamMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandTransforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus — University of Alabama Birmingham Hospital, BirminghamCorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry — CorEvitas, LLC, WalthamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants — Loma Linda University health, Loma LindaREACT-01: Reversing Autoimmunity Through Cell Therapy — Seattle Children's Hospital, SeattleCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanAlnuctamab for Refractory SLE (LATTE Study) — Icahn School of Medicine at Mount Sinai, New YorkTopical Treatment for Atopic Dermatitis — Wake Forest University Health Sciences, Winston-SalemPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease — Boston Children's Hospital, BostonObservational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies — National Institutes of Health Clinical Center, BethesdaEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoStudy to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN — GSK Investigational Site, BaltimoreA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoExercise in Child Health — University of California, Irvine, IrvineThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institutes of Health Clinical Center, BethesdaFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CitySafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkGonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), BethesdaDirect to Patient Minimal Risk Biospecimen and Data Collection Research — Joined Bio, LexingtonA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants — GSK Investigational Site, ScottsdaleA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — University Of Alabama, BirminghamAnifrolumab Pregnancy Study — Research Site, CaryA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — State University of New York Upstate Medical Center (SUNY), SyracuseMichigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project — University of Michigan, Ann ArborPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease — Mayo Clinic, PhoenixDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry — CorEvitas, WalthamA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoStudy to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease — National Institutes of Health Clinical Center, Bethesda

Showing the 150 nearest — narrow your filters for fewer, closer studies.